重药控股(000950) - 2021 Q3 - 季度财报

Revenue and Profit - Revenue for Q3 2021 reached ¥16,107,253,221.04, an increase of 20.64% year-over-year, and cumulative revenue for the year-to-date was ¥46,218,544,640.38, up 51.95% compared to the same period last year[5] - Net profit attributable to shareholders was ¥243,754,548.43, a decrease of 21.90% year-over-year, while year-to-date net profit was ¥681,536,777.92, an increase of 11.40%[5] - Total operating revenue for the current period reached ¥46,218,544,640.38, a significant increase from ¥30,416,410,277.02 in the previous period, representing a growth of approximately 52.1%[28] - Net profit for the current period was ¥886,828,361.67, up from ¥743,145,648.72 in the previous period, reflecting a growth of approximately 19.3%[31] - The net profit attributable to the parent company was ¥681,536,777.92, compared to ¥611,798,689.88 in the prior period, marking an increase of around 11.4%[31] - The total comprehensive income for the current period was ¥884,188,227.21, compared to ¥743,279,028.79 in the previous period, indicating a growth of approximately 19%[31] Cash Flow and Financial Position - The company reported a net cash flow from operating activities of -¥2,841,522,531.92 for the year-to-date, reflecting a cash outflow increase of 162.03%[5] - Operating cash inflow totaled CNY 46,904,271,277.26, an increase from CNY 32,820,021,202.74 year-over-year[35] - Net cash flow from operating activities was CNY -2,841,522,531.92, compared to CNY -1,084,423,532.24 in the previous year[35] - Investment activities generated a net cash flow of CNY -808,948,880.36, improving from CNY -1,503,104,637.75 year-over-year[38] - Cash inflow from financing activities reached CNY 18,549,551,056.93, up from CNY 11,577,457,530.61 in the previous year[38] - Cash outflow for debt repayment was CNY 15,026,825,140.17, compared to CNY 8,027,447,223.63 last year[38] - The company reported a net increase in cash and cash equivalents of CNY -1,124,448,856.81, compared to CNY -607,155,806.68 in the previous year[38] Assets and Liabilities - Total assets as of the end of the reporting period were ¥48,960,462,840.11, representing a 15.38% increase from the end of the previous year[7] - Total assets reached approximately RMB 48.96 billion, compared to RMB 42.43 billion at the end of 2020, marking an increase of about 15.9%[22] - The company's total liabilities amounted to approximately RMB 31.16 billion, up from RMB 27.16 billion, indicating an increase of about 14.8%[22] - The total liabilities increased to ¥37,572,483,814.56 from ¥31,951,885,635.48, showing a rise of approximately 17.9%[28] - Total liabilities amounted to CNY 31,951,885,635.48, with non-current liabilities at CNY 4,789,924,420.93[45] - The company’s total liabilities included short-term borrowings of CNY 9,316,046,412.28[41] Shareholder Information - The total number of common shareholders at the end of the reporting period was 39,106[13] - Chongqing Pharmaceutical Health Industry Co., Ltd. holds 38.14% of shares, totaling 664,900,806 shares[13] - The top three shareholders collectively hold 63.26% of the company's shares, indicating a high concentration of ownership[13] Expenses and Investments - The company experienced a 49.10% increase in selling expenses, totaling ¥1,391,048,005.62, in line with revenue growth[12] - Financial expenses surged by 89.80% to ¥829,473,530.58, influenced by increased interest-bearing liabilities from rapid revenue growth and acquisitions[12] - Research and development expenses for the current period were ¥4,152,443.80, significantly higher than ¥1,365,335.46 in the previous period, representing an increase of approximately 204.5%[29] - The company reported a long-term equity investment of approximately RMB 2.59 billion, an increase from RMB 2.31 billion, reflecting a growth of about 11.7%[22] Inventory and Receivables - Accounts receivable increased by 27.10% to ¥27,612,072,418.82 due to enhanced sales network and rapid revenue growth[9] - Inventory rose by 6.56% to ¥6,023,717,327.85, driven by business expansion and increased stock[9] - Accounts receivable increased to approximately RMB 27.61 billion, up from RMB 21.72 billion, representing a growth of about 27.1% year-over-year[20] - Inventory as of September 30, 2021, was approximately RMB 6.02 billion, an increase from RMB 5.65 billion, reflecting a growth of about 6.5%[20]